一分钟看懂
这是一项关于晚期实体瘤的I 期研究，登记的药物或干预包括BG-C9074；Tislelizumab；Bevacizumab，当前状态为招募中。登记地点显示中国北京、福州、广州、哈尔滨等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
BG-C9074；Tislelizumab；Bevacizumab · I 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Cancer Hospital Chinese Academy of Medical Sciences · 北京
- Fujian Cancer Hospital · 福州
- Sun Yat Sen University Cancer Center · 广州
- Harbin Medical University Cancer Hospital · 哈尔滨
- Union Hospital of Tongji Medical College, Huazhong University of Science and Technology · 武汉
- Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology · 武汉
- The Second Hospital of Dalian Medical University · 大连
- Shengjing Hospital of China Medical University · 沈阳
- Liaoning Cancer Hospital and Institute · 沈阳
- Qilu Hospital of Shandong University · 济南
- Affiliated Hospital of Jining Medical University · 济宁
- Weifang Peoples Hospital · 潍坊
- Obstetrics and Gynecology Hospital of Fudan University · 上海
- Tianjin Medical University Cancer Institute and Hospital · 天津
- Zhejiang Cancer Hospital · 杭州
公开的入选条件
- 1. Able to provide a signed and dated written informed consent prior to any study-specific procedures, sampling, or data collection.
- 2. Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 1.
- 3. Participants with selected histologically or cytologically confirmed advanced, metastatic, and unresectable solid tumors who have previously received standard systemic therapy and whose cancer is not amenable to therapy with curative intent, and for whom fu
- 4. ≥ 1 measurable lesion per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1)
- 5. Able to provide an archived tumor tissue sample.
- 6. Adequate bone marrow and organ function.
- 7. Females of childbearing potential must be willing to use a highly effective method of birth control for the duration of the study, and for ≥ 7 months after the last dose of study drug(s).
- 8. Nonsterile males must be willing to use a highly effective method of birth control for the duration of the study treatment period and for ≥ 4 months after the last dose of study drug(s).
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT06233942；登记信息更新于 2026-09-16。